Related Experiment Video
Updated: Apr 5, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
44.7K
Impact of antipsoriatic therapy on endothelial function
E Cohen-Barak1, M Sah1, M Kerner1
1Department of Dermatology, Haemek Medical Center, Afula, 18101, Israel.
The British Journal of Dermatology
|August 18, 2015
Summary
Short-term psoriasis treatments did not improve endothelial function (EF), a marker for cardiovascular risk. Further research is needed to determine if longer treatment durations or specific patient groups may show benefits in EF for psoriasis patients.
Area of Science:
- Cardiovascular Health
- Dermatology
- Vascular Biology
Background:
- Endothelial function (EF) impairment is an early indicator of atherosclerosis, a condition linked to psoriasis.
- The impact of antipsoriatic therapies, some with potential atherogenic risks, on cardiovascular health and EF remains unclear.
Purpose of the Study:
- To assess the short-term effects of antipsoriatic treatments on endothelial function (EF) as a surrogate marker for cardiovascular risk.
- Investigate changes in microvascular blood flow using the reactive hyperaemia index (RHI) following treatment.
Main Methods:
- Evaluated EF via reactive hyperaemia index (RHI) in 26 moderate-to-severe psoriasis patients.
- Measurements were taken before and after 8 weeks of phototherapy or 12 weeks of systemic antipsoriatic treatment.
Main Results:
- Antipsoriatic interventions were effective in improving psoriasis severity (46% achieved ≥75% PASI improvement).
- Overall average RHI did not significantly change post-treatment (1.73 ± 0.48 vs. 1.66 ± 0.35).
- Patients with initially normal EF showed a trend towards decreased RHI (P=0.053), while those with abnormal baseline RHI had non-significant improvement.
Conclusions:
- Short-term antipsoriatic treatments showed no significant positive impact on endothelial function (EF).
- Longer treatment durations and evaluation periods may reveal endothelial benefits, particularly in patients with pre-existing abnormal EF.
More Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
564
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:29Therapeutic Drug Monitoring: Affecting Factors
339
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
339
01:27Peripheral Artery Disease III: Interprofessional Care
586
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
586
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347